The DOI matches its Crossref record; 64 of the 67 references it cites were found in a registry or an index.
Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane Therapy
Open accessAbstract
Adrenocortical carcinoma is a rare tumor, and only limited information is available about its natural history and the effects of therapy. We studied 105 patients (75 female and 30 male; mean age, 46 years) with adrenocortical carcinoma who were referred to us between 1963 and 1987. The average duration of symptoms before diagnosis was 8.7 months. At the time of diagnosis, 68 percent of the patients had endocrine symptoms, and 30 percent had distant metastases. Hormonal studies showed that 79 percent of the tumors were functional. Eighty patients underwent surgery, and 59 also received the adrenal cytotoxic agent mitotane. The median disease-free interval after surgery was 12.1 months (range, 1 to 175). Tumor dissemination occurred in 82 percent of the patients, most commonly to the lung, liver, and adjacent organs. The median survival time was 14.5 months (range, less than 1 to 175), and the five-year survival was 22 percent. Age over 40 years and the presence of metastases at the time of diagnosis were the only factors recognized as indicating a poor prognosis. Mitotane controlled hormonal secretion in 75 percent of the patients. Eight mitotane-treated patients had partial tumor regression, but the drug did not have a significant effect on survival. We conclude that adrenocortical carcinoma carries a poor prognosis. Mitotane therapy may offer transient benefits, particularly in controlling endocrine symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in accordance with a median age of 46 years in a large single center series in France (10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“In the adult as well as in the pediatric population, there is a predilection for the female gender (the ratio of female to male ranges from 1.5–2.5:1) (10, 17).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“A role of estrogens has also been suggested by the observation of a probable relative increase of diagnosis of ACC during pregnancy (10, 19).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“For 40% to 60% of patients, the major presenting complaints are symptoms and signs of hormone excess (3, 9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Another third present with nonspecific symptoms due to local tumor growth, such as abdominal or flank pain, abdominal fullness, or early satiety (9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Patients with ACC only rarely present with classical tumor symptoms, such as cachexia or night sweats (3, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Biochemically or clinically apparent adrenocortical hormone production is evident in up to 45% to 70% (9, 10, 85).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Hypercortisolism is the most common presentation of patients presenting with hormone excess (50%–80% of hormone-secreting ACCs), causing classic symptoms including plethora, diabetes mellitus, muscle weakness/atrophy, and osteoporosis.”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Murphy, B. E. P. (1967) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-27-7-973 · Cited by 1,998
Incidence of malignant tumors in U.S. children
Young, J. L., & Miller, R. W. (1975) · The Journal of Pediatrics · doi:10.1016/s0022-3476(75)80484-7 · Cited by 842
On Distribution-Free Tests for Equality of Survival Distributions
Tarone, R. E., & Ware, J. S. (1977) · Biometrika · doi:10.1093/biomet/64.1.156 · Cited by 733
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Rubinstein, L. J., Herman, M. M., Long, T. F., & Wilbur, J. R. (1975) · Cancer · doi:10.1002/1097-0142(197502)35:2 · Cited by 383
Results of Treatment in 108 Patients with Cushing's Syndrome
Orth, D. N., & Liddle, G. W. (1971) · New England Journal of Medicine · doi:10.1056/nejm197107292850501 · Cited by 327
Research works printed but not linked: 21
- Plager, 1984, Int Adv Surg Oncol, 7, 329
- Macfarlane, 1958, Ann R Coll Surg Engl, 23, 155
- Heinbecker, 1957, Surg Gynecol Obstet, 105, 21
- Brennan, 1987, CA, 37, 348
- Bradley, 1975, Surg Gynecol Obstet, 141, 507
- Greenberg, 1978, Am Surg, 44, 81
- Ostuni, 1975, Arch Intern Med, 135, 1257, 10.1001/archinte.1975.00330090129015 · DOI
- Haq, 1980, Cancer Treat Rep, 64, 909
- Bricaire, 1977, Nouv Presse Med, 6, 3650
- Rappaport, 1978, Arch Fr Pediatr, 35, 551
- Levine, 1978, Am J Dis Child, 132, 238
- Lejonc, 1978, Nouv Presse Med, 7, 3147
- Pugeat, 1980, Ann Endocrinol, 41, 107
- Cathelineau, 1980, Ann Endocrinol, 41, 65
- Cassan, 1978, Nouv Presse Med, 7, 2153
- Benaily, 1975, Arch Fr Pediatr, 32, 441
- Cariou, 1982, Nouv Presse Med, 11, 2821
- Charbonnel, 1980, Nouv Presse Med, 9, 239
- Jarabak, 1981, JAMA, 246, 1706, 10.1001/jama.1981.03320150054033 · DOI
- Levy, 1985, Ann Pediatr (Paris), 32, 541
- du Rostu, 1987, Presse Med, 16, 951
Cited by
Sorted by citations
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
A Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 907
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759
Integrated genomic characterization of adrenocortical carcinoma
Assié, G., Letouzé, E., Fassnacht, M., Jouinot, A., Luscap, W., Barreau, O., Omeiri, H., Rodriguez, S., Perlemoine, K., René-Corail, F., et al. (2014) · Nature Genetics · doi:10.1038/ng.2953 · Cited by 732
Self-citationFassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Prevalence and natural history of adrenal incidentalomas
Barzon, L., Sonino, N., Fallo, F., Palu, G., & Boscaro, M. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490273 · Cited by 642
Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Self-citationZeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0593 · Cited by 474
Self-citationAbiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435
Self-citationManagement of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Dackiw, A. P. B., Lee, J. E., Gagel, R. F., & Evans, D. B. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0030-7 · Cited by 390
de Reyniès, A., Assié, G., Rickman, D. S., Tissier, F., Groussin, L., René-Corail, F., Dousset, B., Bertagna, X., Clauser, E., & Bertherat, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5678 · Cited by 382
Self-citationSchulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366
Clinical management of adrenocortical carcinoma
Fassnacht, M., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.008 · Cited by 349
Kerkhofs, T. M. A., Verhoeven, R. H. A., van der Zwan, J. M., Dieleman, J. P., Kerstens, M. N., Links, T. P., van de Poll-Franse, L. V., & Haak, H. R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.034 · Cited by 343
An eleven-year experience with adrenocortical carcinoma.
Pommier, R. F., & Brennan, M. F. (1992) · PubMed · Cited by 332
Haak, H. R., Hermans, J., van de Velde, C., Lentjes, E. G. W. M., Goslings, B. M., Fleuren, G. J., & Krans, H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.183 · Cited by 329
Adrenocortical Oncocytic Tumors: Report of 10 Cases and Review of the Literature
Bisceglia, M., Ludovico, O., Mattia, A. D., Ben‐Dor, D., Sandbank, J., Pasquinelli, G., Lau, S. K., & Weiss, L. M. (2004) · International Journal of Surgical Pathology · doi:10.1177/106689690401200304 · Cited by 317
Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization
Stojadinovic, A., Ghossein, R. A., Hoos, A., Nissan, A., Marshall, D., Dudas, M. E., Cordon‐Cardo, C., Jaques, D. P., & Brennan, M. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.941 · Cited by 312
Berruti, A., Terzolo, M., Sperone, P., Pia, A. R., Casa, S. D., Gross, D. J., Carnaghi, C., Casali, P. G., Porpiglia, F., Mantero, F., et al. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01025 · Cited by 308
Clark, O. H., Benson, A. B., Berlin, J. D., Choti, M. A., Doherty, G. M., Engstrom, P. F., Gibbs, J. F., Heslin, M. J., Kessinger, A., Kulke, M. H., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0050 · Cited by 291
Gicquel, C., BERTAGNA, X. Y., Gaston, V., Coste, J., Louvel, A., Baudin, É., Bertherat, J. Y., Chapuis, Y., Duclos, J. M., Schlumberger, M. J., et al. (2001) · PubMed · Cited by 285
Self-citationAdrenocortical cancer: pathophysiology and clinical management
Libé, R., Fratticci, A., & Bertherat, J. Y. (2007) · Endocrine Related Cancer · doi:10.1677/erc.1.01130 · Cited by 271
Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases
Wood, B. J., Abraham, J., Hvizda, J. L., Alexander, H. R., & Fojo, T. (2003) · Cancer · doi:10.1002/cncr.11084 · Cited by 264
de Fraipont, F., El Atifi, M., Cherradi, N., Le Moigne, G., Defaye, G., Houlgatte, R., Bertherat, J., Bertagna, X., Plouin, P.-F., Baudin, E., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1075 · Cited by 261
Self-citationEfficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma
Fassnacht, M., Hahner, S., Polat, B., Koschker, A.-C., Kenn, W., Flentje, M., & Allolio, B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1007 · Cited by 259
Crucitti, F., Bellantone, R., Ferrante, A., Boscherini, M., & Crucitti, P. (1996) · Surgery · doi:10.1016/s0039-6060(96)80164-4 · Cited by 247
Sallah, S., Wan, J. Y., Nguyen, N. P., Vos, P. W., & Sigounas, G. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 47
Prognostic parameters of metastatic adrenocortical carcinoma
Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236
Self-citationGaujoux, S., Mihai, R., Carnaille, B. M. L., Dousset, B. E., Fiori, C., Porpiglia, F., Hellman, P., Iacobone, M., Kraimps, J. L., Donatini, G., et al. (2017) · British journal of surgery · doi:10.1002/bjs.10414 · Cited by 226
Gicquel, C., BERTAGNA, X. Y., Schneid, H., Leblond‐Francillard, M., LUTON, J. P., Girard, F., & Bouc, Y. L. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.6.7911125 · Cited by 224
Self-citationBERTAGNA, X. Y., Guignat, L., Groussin, L., & Bertherat, J. Y. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.06.001 · Cited by 225
Self-citationAdrenocortical carcinoma: the range of appearances on CT and MRI
Bharwani, N., Rockall, A. G., Sahdev, A., Gueorguiev, M., Drake, W., Grossman, A. B., & Reznek, R. H. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.10.5540 · Cited by 215
Management of adrenocortical carcinoma
Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01881.x · Cited by 214
Giovanni Lughezzani, A., Sun, M., Perrotte, P., Claudio Jeldres, A., Alasker, A., Hendrik Isbarn, A., Budäus, L., Shariat, S. F., Guazzoni, G. F., Montorsi, F., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.007 · Cited by 214
Gicquel, C., Raffin‐Sanson, M., Gaston, V., BERTAGNA, X. Y., Plouin, P., Schlumberger, M. J., Louvel, A., LUTON, J. P., & Bouc, Y. L. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4170 · Cited by 213
Self-citationBellantone, R., Ferrante, A., Boscherini, M., Lombardi, C. P., Crucitti, P., Crucitti, F., Favia, G., Borrelli, D., Boffi, L., Capussotti, L., et al. (1997) · Surgery · doi:10.1016/s0039-6060(97)90229-4 · Cited by 210
Else, T., Williams, A. R., Sabolch, A. N., Jolly, S., Miller, B. S., & Hammer, G. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2856 · Cited by 199
Kulke, M. H., Benson, A. B., Bergsland, E. K., Berlin, J. D., Blaszkowsky, L. S., Choti, M. A., Clark, O. H., Doherty, G. M., Eason, J., Emerson, L. L., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0075 · Cited by 195
Latronico, A. C., & Chrousos, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.5.3921 · Cited by 191
Radiotherapy in adrenocortical carcinoma
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer · doi:10.1002/cncr.24331 · Cited by 189
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187
Self-citationKhan, T. S., Imam, H., Juhlin, C. C., Skogseid, B. M., Gröndal, S., Tibblin, S., Wilander, E., Öberg, K., & Eriksson, B. (2000) · Annals of Oncology · doi:10.1023/a:1008377915129 · Cited by 183
Icard, P., Chapuis, Y., Andréassian, B., Bernard, A., & Proye, C. A. G. (1992) · PubMed · Cited by 179
Self-citationOral gossypol in the treatment of metastatic adrenal cancer
Flack, M. R., Pyle, R., Mullen, N., Lorenzo, B., Wu, Y. W., Knazek, R. A., Nisula, B. C., & Reidenberg, M. M. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.4.8473376 · Cited by 177
Altman, D. G., & Stavola, B. L. D. (1994) · Statistics in Medicine · doi:10.1002/sim.4780130402 · Cited by 176
Leboulleux, S., Dromain, C., Bonniaud, G., Auperin, A., Caillou, B., Lumbroso, J., Sigal, R., Baudin, É., & Schlumberger, M. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1540 · Cited by 169
Groussin, L., Jullian, E. H., Perlemoine, K., Louvel, A., Leheup, B., LUTON, J. P., BERTAGNA, X. Y., & Bertherat, J. Y. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020592 · Cited by 168
Self-citationProspective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly
Daffara, F., De Francia, S., Reimondo, G., Zaggia, B., Aroasio, E., Porpiglia, F., Volante, M., Termine, A., Di Carlo, F., Dogliotti, L., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0103 · Cited by 167
Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma
Ahmad, S. A., Liu, W., Jung, Y. D., Fan, F., Reinmuth, N., Bucana, C. D., & Ellis, L. M. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5 · Cited by 110
Adrenocortical Tumors: Recent Advances in Basic Concepts and Clinical Management
Bornstein, S. R., Stratakis, C. A., & Chrousos, G. P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-9-199905040-00017 · Cited by 156
Faßnacht, M., Johanssen, S., Fenske, W., Weismann, D., Agha, A., Beuschlein, F., Führer, D., Jurowich, C. F., Quinkler, M. O., Petersenn, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0803 · Cited by 156
Chortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2851 · Cited by 154
Self-citationThe role of surgery in the management of recurrent adrenocortical carcinoma
Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2559 · Cited by 154
Adrenocortical tumors in children
Çiftçi, A. Ö., Şenocak, M. E., Tanyel, F. C., & Büyükpamukçu, N. (2001) · Journal of Pediatric Surgery · doi:10.1053/jpsu.2001.22280 · Cited by 147
Biology, clinical characteristics, and management of adrenocortical tumors in children
Rodriguez‐Galindo, C., Figueiredo, B. C., Zambetti, G. P., & Ribeiro, R. C. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20318 · Cited by 146
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10 · Cited by 2,098
Veytsman, I. G., Nieman, L. K., & Fojo, T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2775 · Cited by 147
Wong, D., Spagnolo, D. V., Bisceglia, M., Havlat, M. F., McCallum, D., & Platten, M. A. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.08.010 · Cited by 141
Kendrick, M. L. (2001) · Archives of Surgery · doi:10.1001/archsurg.136.5.543 · Cited by 140
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma
Megerle, F., Herrmann, W., Schlötelburg, W., Ronchi, C. L., Pulzer, A., Quinkler, M. O., Beuschlein, F., Hahner, S., Kroiß, M., Faßnacht, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02591 · Cited by 135
Naing, A., LoRusso, P. M., Fu, S., Hong, D. S., Chen, H. X., Doyle, L. A., Phan, A. T., Habra, M. A., & Kurzrock, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.46 · Cited by 134
Kim, Y., Margonis, G. A., Prescott, J. D., Tran, T. B., Postlewait, L. M., Maithel, S. K., Wang, T. S., Evans, D. B., Hatzaras, I. S., Shenoy, R. S., et al. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2015.4516 · Cited by 131
Seccia, T. M., Fassina, A., Nussdorfer, G. G., Pessina, A. C., & Rossi, G. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00867 · Cited by 131
Chiche, L., Dousset, B. E., Kieffer, É., & Chapuis, Y. (2005) · Surgery · doi:10.1016/j.surg.2005.05.014 · Cited by 129
Self-citationWnt/β-catenin signalling in adrenal physiology and tumour development
Berthon, A., Martinez, A., Bertherat, J., & Val, P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.009 · Cited by 125
Hypertension in Cancer Patients and Survivors
Cohen, J. B., Geara, A. S., Hogan, J. J., & Townsend, R. R. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.11.009 · Cited by 127
Abraham, J., Bakke, S., Rutt, A., Meadows, B., Merino, M. J., Alexander, R. H., Schrump, D. S., Bartlett, D., Choyke, P. L., Robey, R. W., et al. (2002) · Cancer · doi:10.1002/cncr.10487 · Cited by 120
Pathologic Features of Prognostic Significance for Adrenocortical Carcinoma After Curative Resection
Harrison, L. E. (1999) · Archives of Surgery · doi:10.1001/archsurg.134.2.181 · Cited by 117
Terzolo, M., Pia, A. R., Berruti, A., Osella, G., Alı̀, A., Carbone, V., Testa, E., Dogliotti, L., & Angeli, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6619 · Cited by 116
Adjuvant and definitive radiotherapy for adrenocortical carcinoma
Sabolch, A., Feng, M., Griffith, K., Hammer, G., Doherty, G., & Ben-Josef, E. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.04.030 · Cited by 115
Mackie, G. C., Shulkin, B. L., Ribeiro, R. C., Worden, F. P., Gauger, P. G., Mody, R. J., Connolly, L. P., Kunter, G., Rodriguez-Galindo, C., Wallis, J. W., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2612 · Cited by 115
Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors
Slater, E. P., Diehl, S. M., Langer, P., Samans, B., Ramaswamy, A., Zielke, A., & Bartsch, D. K. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02116 · Cited by 113
Clonal analysis of human adrenocortical carcinomas and secreting adenomas
Gicquel, C., Leblond‐Francillard, M., Bertagna, X., Louvel, A., Chapuls, Y., Luton, J., Girard, F., & Le Bouc, Y. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02485.x · Cited by 111
Self-citationAdrenal Imaging: A Comprehensive Review
Taffel, M. T., Haji-Momenian, S., Nikolaidis, P., & Miller, F. H. (2012) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2012.02.009 · Cited by 108
Cutaneous fibrosis induced by docetaxel
Cleveland, M. G., Ajaikumar, B. S., & Reganti, R. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5 · Cited by 48
Management of adrenal cancer: a 2013 update
Terzolo, M., Daffara, F., Ardito, A., Zaggia, B., Basile, V., Ferrari, L., & Berruti, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-013-0049-2 · Cited by 109
The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer
O'Sullivan, C. C., Edgerly, M., Velarde, M., Wilkerson, J., Venkatesan, A. M., Pittaluga, S., Yang, S. X., Nguyen, D., Balasubramaniam, S., & Fojo, T. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2298 · Cited by 102
FDG-PET in Adrenocortical Carcinoma
Becherer, A., Vierhapper, H., Pötzi, C., Karanikas, G., Kurtaran, A., Schmaljohann, J., Staudenherz, A., Dudczak, R., & Kletter, K. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497801753131363 · Cited by 102
ADRENOCORTICAL CARCINOMA WITH INTRACAVAL EXTENSION
Hedican, S. P., & Marshall, F. F. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)68152-7 · Cited by 102
Habra, M. A., Ejaz, S., Feng, L., Das, P., Deniz, F., Grubbs, E. G., Phan, A., Waguespack, S. G., Ayala-Ramirez, M., Jimenez, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2367 · Cited by 101
Operative management for recurrent and metastatic adrenocortical carcinoma
Datrice, N., Langan, R. C., Ripley, R. T., Kemp, C. D., Steinberg, S. M., Wood, B. J., Libutti, S. K., Fojo, T., Schrump, D. S., & Avital, I. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.23015 · Cited by 99
Schmitt, A., Saremaslani, P., Schmid, S., Rousson, V, Montani, M., Schmid, D. M., Heitz, P. U., Komminoth, P., & Perren, A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02505.x · Cited by 94
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
Fay, A. P., Signoretti, S., Callea, M., Teló, G. H., McKay, R. R., Song, J., Carvo, I., Lampron, M. E., Kaymakcalan, M. D., Poli‐de‐Figueiredo, C. E., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0047-3 · Cited by 94
Ichijo, T., Ueshiba, H., Nawata, H., & Yanase, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0486 · Cited by 97
TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma
Jain, M., Zhang, L., He, M., Zhang, Y., Shen, M., & Kebebew, E. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0403 · Cited by 87
Nader, N., Raverot, G., Emptoz-Bonneton, A., Déchaud, H., Bonnay, M., Baudin, E., & Pugeat, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2157 · Cited by 89
Postlewait, L. M., Ethun, C. G., Tran, T. B., Prescott, J. D., Pawlik, T. M., Wang, T. S., Glenn, J. A., Hatzaras, I. S., Shenoy, R. S., Phay, J. E., et al. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.12.013 · Cited by 87
Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma
Gonzalez, R. J., Tamm, E. P., Ng, C., Phan, A. T., Vassilopoulou-Sellin, R., Perrier, N. D., Evans, D. B., & Lee, J. E. (2007) · Surgery · doi:10.1016/j.surg.2007.09.006 · Cited by 84
Clinical and prognostic aspects of adrenocortical neoplasms in childhood
Teinturier, C., Pauchard, M. S., Brugi�res, L., Landais, P., Chaussain, J., & Bougn�res, P. F. (1999) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(199902)32:2 · Cited by 84
Gupta, N., Rivera, M., Novotny, P. J., Rodriguez, V., Bancos, I., & Lteif, A. N. (2018) · Hormone Research in Paediatrics · doi:10.1159/000488855 · Cited by 85
Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma
INSERM, A. R. C., Bonacci, R., Gigliotti, A., Baudin, É., Wion-Barbot, N., Emy, P., Bonnay, M., Af, C., Nakib, I., & Schlumberger, M. J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.530 · Cited by 82
Jensen, J. C. (1991) · Archives of Surgery · doi:10.1001/archsurg.1991.01410280059008 · Cited by 81
Approach to the Patient with Adrenocortical Carcinoma
Lacroix, A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0990 · Cited by 81
DIFFERENTIAL DIAGNOSIS AND MANAGEMENT OF CUSHING'S SYNDROME
Tsigos, C., & Chrousos, G. P. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.443 · Cited by 80
Metadata
- Authors
- Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., Bonnin, A., & Bricaire, H.
- Affiliations
- Hôpital Cochin (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1990-04-26
- Volume
- 322
- Issue
- 17
- Pages
- 1195-1201
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2336089418
- Cited by
- 717
- References
- 67
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 15 · 2023: 26 · 2022: 22 · 2021: 31 · 2020: 20 · 2019: 17 · 2018: 23 · 2017: 16 · 2016: 19 · 2015: 27 · 2014: 25 · 2013: 19 · 2012: 31
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- adrenocortical carcinoma, mitotane, prognostic factors, adrenal surgery, metastasis, survival, endocrine symptoms, tumor regression, adrenocortical function, age over 40
- MeSH terms
- Adrenal Cortex Hormones, Adrenal Cortex Neoplasms, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mitotane, Neoplasm Metastasis, Prognosis, Retrospective Studies, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
